Deutsche Bank says that with a number of upcoming catalysts, it sees an attractive risk/reward...
Monday, June 18, 2012, 3:23 PM ETDeutsche Bank says that with a number of upcoming catalysts, it sees an attractive risk/reward profile in Teva (TEVA +0.2%) at current levels. The firm targets a $10 potential upside on the shares, with $3 potential downside. The firm reiterates its Buy rating with a $48 price target.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles